Indefinite Delivery Contract SPE2D219D0077

The federal contract IDV award SPE2D219D0077 was issued by the Department of Defense's Defense Logistics Agency (DLA) to The Harvard Drug Group, L.L.C. as a single-award indefinite delivery contract. The $21,366,302.60 contract, awarded on September 5, 2019, is for the manufacture and distribution of a range of pharmaceutical products and medical supplies, including various generic medications, over-the-counter drugs, and topical creams and ointments.

The original competitive solicitation, posted on March 14, 2019, sought to establish a national requirements contract for fexofenadine hydrochloride tablets in 60mg and 180mg strengths for use by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons through the DLA and VA prime vendor programs. As a commercial item contract under FAR Part 12, the award was not set aside and was open to all sources. The contract has a one-year base period with four one-year option periods, running through September 11, 2024. The Harvard Drug Group, through its Major Pharmaceuticals and Rugby Laboratories divisions, has demonstrated the capacity to fulfill large-scale, multi-agency pharmaceutical supply contracts for the federal government.